Free Trial
NASDAQ:IMNM

Immunome Q1 2024 Earnings Report

Immunome logo
$9.87 -0.59 (-5.64%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$10.01 +0.14 (+1.37%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.80
Beat/Miss
Beat by +$0.46
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
$1.03 million
Expected Revenue
$4.00 million
Beat/Miss
Missed by -$2.97 million
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Immunome's Q3 2025 earnings is scheduled for Monday, August 11, 2025

Immunome Earnings Headlines

Immunome (IMNM) Q2 Revenue Surges 382%
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM), a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

View Immunome Profile

More Earnings Resources from MarketBeat